Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.78 |
| ▸ | FLT3 | P36888 | 9/20 | 0.78 |
| ▸ | KIT | P10721 | 8/20 | 0.78 |
| ▸ | CSF1R | P07333 | 7/20 | 0.78 |
| ▸ | FLT1 | P17948 | 7/20 | 0.78 |
| ▸ | FLT4 | P35916 | 7/20 | 0.78 |
| ▸ | LYN | P07948 | 6/20 | 0.78 |
| ▸ | BLK | P51451 | 6/20 | 0.78 |
| ▸ | LCK | P06239 | 6/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.74 |
| ▸ | RET | P07949 | 3/20 | 0.74 |
| ▸ | MET | P08581 | 3/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.74 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.74 |
| ▸ | FRK | P42685 | 3/20 | 0.74 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703074 | 0.89 | KDR (0.78) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702879 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702951 | 0.85 | KDR (0.80) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702967 | 0.85 | KDR (1.00) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702965 | 0.83 | KDR (0.79) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702898 | 0.82 | KDR (1.00) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1703600 | 0.82 | KDR (0.78) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1703583 | 0.81 | KIT (1.00) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL5315990 | 0.80 | KDR (0.55) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1703302 | 0.78 | KDR (0.79) | KDRFLT3KITCSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | claimed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | claimed |
| US-7812166-B2 | Kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | KDR 434/4885FLT3 79/4885KIT 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.